EYPT
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
EyePoint Pharmaceuticals, Inc.
- Nom
- EyePoint Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $33.9M
- Employés
- 214
- PDG
- Jay S. Duker
- Site web
- https://www.eyepoint.bio
- Marché
- BCAXKODKURANRIXPRMEPROK
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 10 600 titres (~52 258,00 $ US)
- Insiders
- Zaderej Karen L.
- Total bought
-
$52,258
Avg buy (VWAP, 90d window) $4.93 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | Zaderej Karen L. | Buy · P | 10,600 | $4.93 | $52,258 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
EYPT presents a catastrophic risk profile: the Phase 3 failure of DURAVYU (LUGANO trial, primary endpoint missed) triggered a 67% stock collapse, and with a catalyst score of just 10 and no meaningful positive…
The first sentence of the analysis written for EYPT on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 8.88 · operating margin -776% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 93.4% | 91.4% | 89.9% | 79.9% | 77.9% | |
| Ebit Margin | -738.4% | -302.2% | -151.0% | -239.3% | -143.3% | |
| Ebitda Margin | -731.1% | -298.6% | -149.9% | -233.4% | -135.8% | |
| Operating Profit Margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | |
| Pretax Profit Margin | -738.5% | -302.2% | -153.7% | -247.0% | -158.1% | |
| Continuous Operations Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Net Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Bottom Line Profit Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | |
| Current Ratio | 8.877 | 7.815 | 5.450 | 5.004 | 10.049 | |
| Quick Ratio | 8.828 | 7.768 | 5.389 | 4.920 | 9.896 | |
| Solvency Ratio | -3.968 | -1.578 | -0.791 | -1.188 | -0.704 | |
| Cash Ratio | 2.750 | 2.033 | 4.446 | 2.769 | 7.549 | |
| Price To Earnings Ratio | -5.763 | -3.211 | -12.698 | -1.277 | -6.030 | |
| Price To Earnings Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Forward Price To Earnings Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Price To Earnings Diluted Ratio | -5.763 | -3.211 | -12.698 | -1.277 | -6.030 | |
| Price To Earnings Diluted Growth Ratio | -0.157 | -0.117 | 0.378 | -0.037 | 0.141 | |
| Price To Book Ratio | 4.372 | 1.246 | 3.376 | 1.355 | 1.909 | |
| Price To Sales Ratio | 42.660 | 9.692 | 19.537 | 3.155 | 9.529 | |
| Price To Free Cash Flow Ratio | -5.499 | -3.219 | -559.124 | -1.945 | -7.005 | |
| Price To Operating Cash Flow Ratio | -5.574 | -3.323 | 479.505 | -2.009 | -7.026 | |
| Debt To Assets Ratio | 0.063 | 0.052 | 0.014 | 0.257 | 0.149 | |
| Debt To Equity Ratio | 0.074 | 0.065 | 0.018 | 0.481 | 0.213 | |
| Debt To Capital Ratio | 0.069 | 0.061 | 0.018 | 0.325 | 0.175 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.233 | 0.165 | |
| Financial Leverage Ratio | 1.189 | 1.244 | 1.334 | 1.872 | 1.428 | |
| Working Capital Turnover Ratio | 0.100 | 0.141 | 0.219 | 0.235 | 0.282 | |
| Operating Cash Flow Ratio | -6.485 | -2.574 | 0.030 | -1.882 | -2.118 | |
| Operating Cash Flow Sales Ratio | -7.654 | -2.917 | 0.041 | -1.570 | -1.356 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.032 | -0.858 | 1.033 | 1.003 | |
| Debt Service Coverage Ratio | 6,958.182 | -9,236.857 | -55.400 | -7.071 | -9.121 | |
| Interest Coverage Ratio | 7,376.788 | -10,418.143 | -60.198 | -31.244 | -10.054 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -6.206 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.534 | -5.775 | 0.382 | -1.403 | -1.278 | |
| Capital Expenditure Coverage Ratio | -73.204 | -31.152 | 0.538 | -30.235 | -321.135 | |
| Dividend Paid And Capex Coverage Ratio | -73.204 | -31.152 | 0.538 | -30.235 | -321.135 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.491 | -2.643 | -9.025 | -0.842 | -4.240 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 93.4% | ▲2.0% | ▲6.9% |
| Ebit Margin | -738.4% | ▼-436.2% | ▼-423.6% |
| Ebitda Margin | -731.1% | ▼-432.4% | ▼-421.3% |
| Operating Profit Margin | -776.0% | ▼-438.9% | ▼-442.7% |
| Pretax Profit Margin | -738.5% | ▼-436.3% | ▼-418.6% |
| Continuous Operations Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Net Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Bottom Line Profit Margin | -739.4% | ▼-437.0% | ▼-419.3% |
| Current Ratio | 8.877 | ▲1.062 | ▲1.438 |
| Quick Ratio | 8.828 | ▲1.060 | ▲1.468 |
| Solvency Ratio | -3.967 | ▼-2.390 | ▼-2.322 |
| Cash Ratio | 2.750 | ▲0.717 | ▼-1.159 |
| Price To Earnings Ratio | -5.763 | ▼-2.552 | ▲0.033 |
| Price To Earnings Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Forward Price To Earnings Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Price To Earnings Diluted Ratio | -5.763 | ▼-2.552 | ▲0.033 |
| Price To Earnings Diluted Growth Ratio | -0.157 | ▼-0.040 | ▼-0.199 |
| Price To Book Ratio | 4.372 | ▲3.126 | ▲1.920 |
| Price To Sales Ratio | 42.660 | ▲32.968 | ▲25.745 |
| Price To Free Cash Flow Ratio | -5.499 | ▼-2.279 | ▲109.860 |
| Price To Operating Cash Flow Ratio | -5.574 | ▼-2.251 | ▼-97.888 |
| Debt To Assets Ratio | 0.063 | ▲0.010 | ▼-0.044 |
| Debt To Equity Ratio | 0.074 | ▲0.009 | ▼-0.096 |
| Debt To Capital Ratio | 0.069 | ▲0.008 | ▼-0.060 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.080 |
| Financial Leverage Ratio | 1.189 | ▼-0.054 | ▼-0.224 |
| Working Capital Turnover Ratio | 0.100 | ▼-0.040 | ▼-0.095 |
| Operating Cash Flow Ratio | -6.485 | ▼-3.912 | ▼-3.880 |
| Operating Cash Flow Sales Ratio | -7.654 | ▼-4.737 | ▼-4.963 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▼-0.018 | ▲0.369 |
| Debt Service Coverage Ratio | 6958.182 | ▲16195.039 | ▲7428.235 |
| Interest Coverage Ratio | 7376.788 | ▲17794.931 | ▲8005.358 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲1.241 |
| Operating Cash Flow Coverage Ratio | -10.534 | ▼-4.759 | ▼-6.812 |
| Capital Expenditure Coverage Ratio | -73.204 | ▼-42.053 | ▲17.833 |
| Dividend Paid And Capex Coverage Ratio | -73.204 | ▼-42.053 | ▲17.833 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.491 | ▼-2.848 | ▼-1.043 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.34B | $419.4M | $899.1M | $130.6M | $352.0M | |
| Enterprise value | $1.26B | $341.6M | $622.7M | $81.3M | $212.6M | |
| EV / Sales | 40.14x | 7.89x | 13.53x | 1.96x | 5.76x | |
| EV / Op. cash flow | -5.25x | -2.71x | 332.11x | -1.25x | -4.24x | |
| EV / Free cash flow | -5.17x | -2.62x | -387.26x | -1.21x | -4.23x | |
| EV / EBITDA | -5.49x | -2.64x | -9.03x | -0.84x | -4.24x | |
| Net debt / EBITDA | 0.34x | 0.60x | 4.00x | 0.51x | 2.78x | |
| Current ratio | 8.88x | 7.82x | 5.45x | 5.00x | 10.05x | |
| Income quality | 1.03x | 0.96x | -0.03x | 0.64x | 0.86x | |
| Graham net-net | $3 | $5 | $6 | $2 | $5 | |
| Tax burden | 100.1% | 100.1% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 101.8% | 103.2% | 110.4% | |
| Working capital | $291.6M | $334.3M | $281.5M | $138.3M | $214.1M | |
| Invested capital | $311.9M | $363.4M | $291.8M | $145.7M | $239.6M | |
| Return on assets | -63.7% | -31.3% | -19.9% | -56.7% | -22.2% | |
| Operating ROA | -62.2% | -37.7% | -28.0% | -44.9% | -31.1% | |
| Return on tangible assets | -63.7% | -31.3% | -19.9% | -56.7% | -24.3% | |
| Return on equity | -75.8% | -38.9% | -26.6% | -106.1% | -31.7% | |
| Return on invested capital | -74.0% | -39.5% | -25.7% | -63.5% | -23.0% | |
| Return on capital employed | -74.5% | -39.5% | -25.7% | -68.3% | -23.1% | |
| Earnings yield | -17.3% | -31.2% | -7.9% | -78.3% | -16.6% | |
| Free cash flow yield | -18.2% | -31.1% | -0.2% | -51.4% | -14.3% | |
| Capex / Op. cash flow | -1.4% | -3.2% | 185.8% | -3.3% | -0.3% | |
| Capex / Depreciation | 142.1% | 263.1% | 750.6% | 87.9% | 5.6% | |
| Capex / Sales | 10.5% | 9.4% | 7.6% | 5.2% | 0.4% | |
| SG&A / Sales | 164.8% | 121.3% | 112.5% | 145.7% | 143.7% | |
| R&D / Sales | 704.6% | 307.2% | 140.5% | 119.9% | 77.2% | |
| Stock comp / Sales | 88.8% | 84.9% | 26.2% | 34.2% | 20.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 8.6% | |
| Days sales outstanding | 8d | 5d | 6d | 137d | 181d | |
| Days payables outstanding | 1853d | 1153d | 513d | 259d | 330d | |
| Operating cycle | 328d | 232d | 314d | 263d | 343d | |
| Cash conversion cycle | -1525d | -921d | -198d | 4d | 13d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-21 EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the
- 2026-08-21 EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company''s disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at.
- 2026-08-20 EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PR
- 2026-08-19 EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT''s management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the Duravyu program and restore investor confidence.
- 2026-08-19 EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial Eyepoint Pharmaceuticals (NASDAQ: EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the full analysis population versus on-label aflibercept. LUGANO enrolled 432 patients, randomized equally to
- 2026-08-18 These Analysts Slash Their Forecasts On EyePoint EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.
- 2026-08-18 EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal EyePoint''s Duravyu misses the phase III wet AMD study''s primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
- 2026-08-18 EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
- 2026-08-17 EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study EyePoint Inc. (NASDAQ:EYPT) stock plunged on Monday after the company released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.
- 2026-08-17 EyePoint''s eye drug misses main goal in late-stage trial EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.